Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
NCT ID: NCT00850304
Last Updated: 2009-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
10 participants
INTERVENTIONAL
2007-10-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
NCT00513305
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
NCT00195104
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
NCT00006092
Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
NCT03751917
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT00093483
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We select ten patients with age further than 60 with comorbidity and treat by low dose cytosar subcutaneous plus arsenic trioxide for ten days in month. We will assess overall response rate and overall survival in end of one year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm one
Cytosar
Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
Arsenic trioxide
Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cytosar
Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
Arsenic trioxide
Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance status (ECOG) 3 or 4
Exclusion Criteria
* Elevation of AST OR ALT more than ten times above normal
* Serum bilirubin above 5
* Cr level \> 2
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hematology-Oncology and SCT Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kamran Alimoghaddam, M.D.
Role: STUDY_DIRECTOR
Hematology-Oncology and SCT Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology-Oncology and SCT Research Center
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87-02-36-7242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.